リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Harada, Kaito Morita-Fujita, Mari Fukuda, Takahiro Ozawa, Yukiyasu Doki, Noriko Toyosaki, Masako Maruyama, Yumiko Kanda, Yoshinobu Ashida, Takashi Eto, Tetsuya Takada, Satoru Uchida, Naoyuki Ichinohe, Tatsuo Kanda, Junya Onizuka, Makoto Atsuta, Yoshiko Kako, Shinichi Arai, Yasuyuki 京都大学 DOI:10.1016/j.jcyt.2022.03.004

2022.09

概要

BACKGROUND AIMS: An intensified conditioning regimen incorporating medium-dose etoposide (VP16) is an option for patients with acute lymphoblastic leukemia (ALL). However, the prognostic impacts of the addition of VP16 to cyclophosphamide (CY) and total body irradiation (TBI) in patients with Philadelphia chromosome-positive (Ph+) ALL with regard to minimal residual disease (MRD) status have not been elucidated. METHODS: The authors retrospectively compared the outcomes of patients with Ph+ ALL who underwent allogeneic transplantation following VP16/CY/TBI (n = 101) and CY/TBI (n = 563). RESULTS: At 4 years, the VP16/CY/TBI group exhibited significantly better disease-free survival (DFS) (72.6% versus 61.7%, P = 0.027) and relapse rate (11.5% versus 21.1%, P = 0.020) and similar non-relapse mortality (16.0% versus 17.2%, P = 0.70). In subgroup analyses, the beneficial effects of the addition of VP16 on DFS were more evident in patients with positive MRD status (71.2% versus 48.4% at 4 years, P = 0.022) than those with negative MRD status (72.8% versus 66.7% at 4 years, P = 0.24). Although MRD positivity was significantly associated with worse DFS in patients who received CY/TBI (48.4% versus 66.7%, P < 0.001), this was not the case in those who received VP16/CY/TBI (71.2% versus 72.8%, P = 0.86). CONCLUSIONS: This study demonstrated the benefits of the addition of VP16 in Ph+ ALL patients, especially those with positive MRD status. VP16/CY/TBI could be a potential strategy to overcome the survival risk of MRD positivity.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

[1] Ravandi F. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2019;133:130–6.

[2] Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of Philadelphia Chromo- some-Positive Acute Lymphoblastic Leukemia. Curr Treat Options Oncol 2019;20:4.

[3] Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, et al. Random- ized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 2015;125:3711–9.

[4] Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, et al. UKALLXII/ ECOG2993: addition of imatinib to a standard treatment regimen enhances long- term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014;123:843–50.

[5] Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, et al. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Adv 2016;1:250–9.

[6] Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treat- ment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2015;121:4158–64.

[7] Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, et al. Dasati- nib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 2018;36:2306–14.

[8] Nakamura M, Arai Y, Hirabayashi S, Kondo T, Doki N, Uchida N, et al. Residual dis- ease is a strong prognostic marker in patients with acute lymphoblastic leukae- mia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation. Br J Haematol 2021;194(2):403–13.

[9] Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lym- phoblastic leukemia. Blood 2015;126:746–56.

[10] Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant 2016;51:43–50.

[11] Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Child- ren's Oncology Group study AALL0232. Blood 2015;126:964–71.

[12] Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, et al. Impact of com- plete molecular response on survival in patients with Philadelphia chromosome- positive acute lymphoblastic leukemia. Blood 2016;128:504–7.

[13] Shigematsu A, Tanaka J, Suzuki R, Atsuta Y, Kawase T, Ito YM, et al. Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia. Int J Hematol 2011;94:463–71.

[14] Shigematsu A, Ozawa Y, Onizuka M, Fujisawa S, Suzuki R, Atsuta Y, et al. A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. Transplant Direct 2015;1:e8.

[15] Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, et al. Improved prog- nosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults. Am J Hematol 2018;93:47–57.

[16] Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 2014;28:658–65.

[17] Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA- related data). Int J Hematol 2016;103:3–10.

[18] Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol 2016;103:11–9.

[19] Arai Y, Takeda J, Aoki K, et al. Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. Blood 2015;126:415–22.

[20] Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.

[21] Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplan- tation. Semin Hematol 1991;28:250–9.

[22] Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medi- cal statistics. Bone Marrow Transplant 2013;48:452–8.

[23] Chang TT, Gulati SC, Chou TC, Vega R, Gandola L, Ibrahim SM, et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelo- cytic leukemia cell line (HL-60) demonstrated by computer analysis. Cancer Res 1985;45:2434–9.

[24] Mu€hl H, Nold M, Chang JH, Frank S, Eberhardt W, Pfeilschifter J. Expression and release of chemokines associated with apoptotic cell death in human promono- cytic U937 cells and peripheral blood mononuclear cells. Eur J Immunol 1999;29:3225–35.

[25] Imamura M, Shigematsu A. Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning. Exp Hematol Oncol 2015;4:20.

[26] Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoi- etic stem cell transplantation for high-risk acute leukemia. Haematologica 2002;87:52–8.

[27] Imamura M, Shigematsu A. Perspectives on the Use of a Medium-Dose Etoposide, Cyclophosphamide, and Total Body Irradiation Conditioning Regimen in Alloge- neic Hematopoietic Stem Cell Transplantation: The Japanese Experience from 1993 to Present. J Clin Med 2019;8:569. Toubai T, Tanaka J, Mori A, Hashino S, Kobayashi S, Ota S, et al. Efficacy of etopo- side, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies. Clin Trans- plant 2004;18:552–7.

[28] Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, et al. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. Biol Blood Marrow Transplant 2017;23:618–24.

[29] Spitzer TR, Peters C, Ortlieb M, Tefft MC, Torrisi J, Cahill R, et al. Etoposide in com- bination with cyclophosphamide and total body irradiation or busulfan as condi- tioning for marrow transplantation in adults and children. Int J Radiat Oncol Biol Phys 1994;29:39–44.

[30] Tazawa Y, Shigematsu A, Kasashi K, Sugita J, Endo T, Kondo T, et al. Pharmacoki- netics and dose adjustment of etoposide administered in a medium-dose etopo- side, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation. J Pharm Health Care Sci 2016;2:18.

[31] Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High com- plete remission rate and promising outcome by combination of imatinib and che- motherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006;24:460–6.

[32] Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leu- kemia. Blood 2010;116:2070–7.

[33] Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associ- ated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009;27:5202–7.

[34] Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Obla€nder J, et al. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood 2018;131:1464–75.

[35] Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combina- tion of hyper-CVAD with ponatinib as first-line therapy for patients with Phila- delphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 2015;16:1547–55.

[36] Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leu- kemia. N Engl J Med 2016;375:740–53.

[37] Stock W, Martinelli G, Stelljes M, DeAngelo DJ, Go€kbuget N, Advani AS, et al. Effi- cacy of inotuzumab ozogamicin in patients with Philadelphia chromosome- positive relapsed/refractory acute lymphoblastic leukemia. Cancer 2021;127:905–13.

[38] Martinelli G, Boissel N, Chevallier P, Ottmann O, Go€kbuget N, Topp MS, et al. Com- plete hematologic and molecular response in adult patients with relapsed/refrac- tory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, sin- gle-arm, multicenter Study. J Clin Oncol 2017;35:1795–802.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る